phosphocreatine comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-01. Numbers and descriptions here follow the published literature rather than marketing material.
In animals, creatine is synthesized mainly in liver, kidney, and pancreas from arginine, glycine, and methionine. The first committed step transfers a guanidino group from arginine to glycine, forming guanidinoacetate. Subsequent methylation by S-adenosylmethionine yields creatine. Dietary sources include meat and fish; endogenous synthesis supplies part of the body pool. Most creatine is stored in skeletal muscle, where it is converted to phosphocreatine and participates in rapid regeneration of adenosine triphosphate during short, intense activity.
Commercial creatine products appear in several forms, including monohydrate, hydrochloride, citrate, nitrate, and ethyl ester. Creatine monohydrate is the most studied form and serves as a reference material in comparative research. Different forms vary in solubility, pH, and water content, but they share creatine as the active moiety after dissolution. Claims that one form is uniformly superior remain debated, and study designs often differ in population, exercise protocol, and outcome measures. Purity and hydration state are central to interpreting product labels.
Creatine monohydrate is the hydrated form of creatine, a nitrogen-containing organic acid involved in cellular energy transfer. Its molecular formula is C4H11N3O3, and it consists of creatine plus one water molecule in the crystal lattice. The anhydrous base, creatine, has the formula C4H9N3O2. The compound appears as a white, odorless, crystalline powder and is classified as a guanidine derivative. It is distinct from creatinine, a breakdown product measured in clinical chemistry.
Stability studies typically examine the effects of temperature, humidity, and light on creatine monohydrate. Sealed containers stored in cool, dry conditions help limit moisture uptake and hydrolysis. Elevated temperature and high relative humidity can accelerate conversion to creatinine, especially in aqueous solutions. In solid dosage forms, excipients and processing steps may also affect stability. Published stability data are not fully consistent across studies because test conditions and analytical methods vary.
Quality control of creatine monohydrate relies on a combination of identity, purity, and moisture tests. High-performance liquid chromatography with ultraviolet detection is widely used to separate creatine from creatinine and other related nitrogenous compounds. Spectroscopic methods such as infrared and nuclear magnetic resonance provide structural confirmation. Because the material is a hydrate, water content is measured separately, often by Karl Fischer titration. These tests together establish whether a lot meets a defined specification.
| Property | Value | Notes |
|---|---|---|
| Chemical formula (monohydrate) | C4H11N3O3 | Includes one water molecule per creatine unit. |
| Molecular weight | 149.15 g/mol | Calculated for the monohydrate; anhydrous creatine is 131.13 g/mol. |
| Appearance | White crystalline powder | Odorless; particle size can vary by manufacturing. |
| CAS Registry Number | 6020-87-7 | Identifies creatine monohydrate; creatine base is 57-00-1. |
| Common synonyms | Creatine hydrate; methylguanidoacetic acid monohydrate | Naming varies by registry and supplier. |
Stability studies examine how creatine monohydrate changes under controlled temperature and humidity. The solid is generally stable when kept dry, but moisture can promote hydrolysis to creatinine, especially in solution or at elevated temperatures. Color, odor, and assay values are monitored over time to detect degradation. Because degradation pathways depend on storage conditions, shelf-life claims should specify the tested packaging, temperature, and humidity. Open questions remain about the long-term behavior of different crystal habits and particle sizes.
Regulatory treatment of creatine monohydrate varies by country and intended use. In some jurisdictions it is sold as a dietary supplement, while in others it may be treated as a food ingredient or a pharmaceutical raw material. Pharmacopeial monographs, where available, define identification, assay limits, and impurity thresholds. Manufacturers often follow these monographs or internal specifications to ensure batch-to-batch consistency. Analytical method validation is important because different methods can yield different apparent purity values if sample preparation or detection conditions are not controlled.
Solid creatine monohydrate is generally stable when kept cool and dry, but it can hydrolyze to creatinine over time. Moisture, heat, and acidic conditions accelerate this conversion, which reduces assay values and changes the material's properties. Creatinine is a cyclic dehydration product that is also a normal human metabolite, so its presence in a sample is not necessarily a health concern by itself. In quality testing, creatinine is monitored as a marker of degradation and purity.
Identity and purity are assessed with several complementary methods. High-performance liquid chromatography can separate creatine from creatinine and related impurities, often with ultraviolet detection. Nuclear magnetic resonance and infrared spectroscopy provide structural confirmation, while Karl Fischer titration measures water content. Elemental analysis and mass spectrometry may be used for additional confirmation, especially in research or forensic settings. No single method captures every quality attribute, so laboratories typically combine results and compare them against a specification.
Creatine monohydrate is a crystalline compound formed from creatine and one molecule of water. Its systematic name is N-(aminoiminomethyl)-N-methylglycine monohydrate, and it appears as a white, odorless powder with limited solubility in water. The monohydrate is the most common solid form used in research and commercial products because it is stable under dry conditions. The anhydrous form lacks the water of crystallization and differs slightly in molar mass. Both forms participate in the same biochemical reactions once dissolved.
In the body, creatine is synthesized from the amino acids arginine, glycine, and methionine, primarily in the liver and kidneys. It is transported to muscle and other tissues, where it is phosphorylated to phosphocreatine by creatine kinase. This phosphagen system provides a rapid source of adenosine triphosphate during short, intense contractions. Dietary creatine comes mainly from meat and fish, and the body's total pool is influenced by both synthesis and intake.
As a supplement, creatine monohydrate is studied for its effects on muscle performance and recovery. The compound is often described as an ergogenic aid, meaning it may support physical work capacity. Research typically compares it with placebo or other forms, such as citrate or nitrate, under controlled conditions. Questions remain about the optimal dose and long-term effects in different populations, and findings are not uniform across all studies. The monohydrate form remains the most extensively tested.
Analytical methods for creatine monohydrate focus on identity, purity, and degradation products. High-performance liquid chromatography with ultraviolet detection is common, often at a wavelength near 210 nanometers. Titration and nuclear magnetic resonance spectroscopy can also quantify the parent compound. Pharmacopeial monographs specify tests for appearance, solubility, water content, and related substances, including creatinine. Purity values above 99 percent are typical for pharmaceutical-grade material, though supplement-grade products vary. Independent verification can detect label discrepancies.
Sourcing and verification of creatine monohydrate involve both manufacturing origin and third-party testing. Industrial production commonly starts with sarcosine and cyanamide, followed by crystallization to obtain the monohydrate. Some products are derived from animal sources, while others are synthesized from non-animal precursors. Certificates of analysis report assay, heavy metals, and microbial limits. Regulations differ by country: in the United States it is sold as a dietary supplement, whereas in the European Union it falls under food supplement rules.
Immunoliposome therapy is a targeted drug delivery method that involves the use of liposomes (artificial lipid bilayer vesicles) coupled with monoclonal antibodies to deliver therapeutic agents to specific sites or tissues in the body. The antibody modified liposomes target tissue through cell-specific antibodies with the release of drugs contained within the assimilated liposomes. Immunoliposome aims to improve drug stability, personalize treatments, and increased drug efficacy. This form of therapy has been used to target specific cells, protecting the encapsulated drugs from degradation in order to enhance their stability, to facilitate sustained drug release and hence to advance current traditional cancer treatment.
== Reaction == Penning ionization refers to the interaction between an electronically excited gas-phase atom G* and a target molecule M. The collision results in the ionization of the molecule yielding a cation M+●, an electron e−, and a neutral gas molecule, G, in the ground state. Penning ionization occurs via formation of a high energy collision complex, evolving toward the formation of a cationic species, by ejecting a high energy electron.
=== Storage === All vegetables benefit from proper post harvest care. A large proportion of vegetables and perishable foods are lost after harvest during the storage period. These losses may be as high as thirty to fifty percent in developing countries where adequate cold storage facilities are not available. The main causes of loss include spoilage caused by moisture, moulds, micro-organisms, and vermin.
=== Ventricular assist device === Collaboration between NASA, Dr. Michael DeBakey, Dr. George Noon, and MicroMed Technology Inc. resulted in a heart pump for patients awaiting heart transplants. The MicroMed DeBakey ventricular assist device (VAD) functions as a "bridge to heart transplant" by pumping blood until a donor heart is available. The pump is approximately one-tenth the size of other currently marketed pulsatile VADs. Because of the pump's small size, fewer patients developed device-related infections. It can operate up to 8 hours on batteries, giving patients the mobility to do normal, everyday activities.
For instance, less than half of those species found in Turkey are actually native. These have been referred to as neo-tulipae. Tulips are indigenous to mountainous areas with temperate climates, where they are a common element of steppe and winter-rain Mediterranean vegetation. They thrive in climates with long, cool springs and dry summers. Tulips are most commonly found in meadows, steppes and chaparral, but also introduced in fields, orchards, roadsides and abandoned gardens.
Sources: en.wikipedia.org
Wakame (Undaria pinnatifida) is a species of kelp native to cold, temperate coasts of the northwest Pacific Ocean. As an edible seaweed, it has a subtly sweet, but distinctive and strong flavour and satiny texture. It is most often served in soups and salads. Wakame has long been collected for food in East Asia, and sea farmers in Japan have cultivated wakame since the eighth century (Nara period). Although native to cold, temperate coastal areas of Japan, Korea, China, and Russia, it has established itself in temperate regions around the world, including New Zealand, the United States, Belgium, France, Great Britain, Spain, Italy, Argentina, Australia and Mexico. As of 2018, the Invasive Species Specialist Group has listed the species on its list of 100 worst globally invasive species. Wakame, as with all other kelps and brown algae, is plant-like in appearance, but is unrelated to true plants, being, instead, a photosynthetic, multicellular stramenopile protist of the SAR supergroup.
Dutasteride, sold under the brand name Avodart among others, is a medication primarily used to treat the symptoms of a benign prostatic hyperplasia (BPH), an enlarged prostate not associated with cancer. It is also used to treat pattern hair loss in men as an off-label medication and as an approved medication in South Korea, Japan, and Taiwan. A few months may be required before benefits occur. It is usually taken by mouth; however, topical versions exist for those with hair loss, which are designed to minimize systemic exposure by acting specifically on hair follicles. The most commonly reported side effects of dutasteride, although rare, include sexual dysfunction. In the largest available study of 6,729 men with BPH, 9% experienced erectile dysfunction (compared to 5.7% treated with a placebo), 3.3% experienced decreased sex drive (vs 1.6% of placebo), and 1.9% had enlarged breasts (vs 1% of placebo). Exposure during pregnancy is specifically contraindicated because antiandrogens such as dutasteride have been shown to interfere with the sexual development of male fetuses. Dutasteride was patented in 1993 by Glaxo Wellcome (later known as GSK after additional mergers) and was approved for medical use in 2001. It is available as a generic medication and as such, manufactured and exported more by India than elsewhere. In 2023, it was the 236th most commonly prescribed medication in the US with more than 1 million prescriptions.
== Function == The protein encoded by this gene is a member of the homeodomain family of DNA binding proteins. It regulates gene expression, morphogenesis, and differentiation and it also plays a role in cell cycle progression, particularly at S-phase. Several alternatively spliced transcript variants of this gene have been described, but the full-length nature of some of these variants has not been determined, and the p200 isoform of Cux1 is processed proteolytically to smaller active isoforms, such as p110. Cux1 DNA binding is stimulated by activation of the PAR2/F2RL1 cell-surface G-protein-coupled receptor in fibroblasts and breast-cancer epithelial cells to regulate Matrix metalloproteinase 10, Interleukin1-alpha, and Cyclo-oxygenase 2 (COX2) genes. Multiple reviews have detailed the tissue-specific functions and genetic interactions in Drosophila and the early characterization of the CDP in mammalian cells, expression and activity of CUX1 in the myeloid cell lineage, multiple CUX1 isoforms, modes of DNA binding, early mouse models and cell-based assays, roles of CUX1 in kidney development and homeostasis, mechanisms by which CUX1 stimulates cell migration and invasion, roles of CUX1 and CUX2 in neurons of the cortex upper layer and the paradoxical implications of CUX1 in cancer. In addition, a number of commentaries present more specific views and speculations.
== Career == Somogyi was born on March 7, 1883, in the village of Zsámánd in Hungary (today Reinersdorf, part of Heiligenbrunn, Austria). He graduated in chemical engineering from the University of Budapest in 1905. After an additional year as an assistant in biochemistry, Somogyi went to the United States, where he eventually found a position as an assistant in biochemistry at Cornell University (1906–1908). He returned to Budapest where he worked at the Municipal Laboratory for the next decade. In 1914, he received his Ph.D. from the University of Budapest, submitting a dissertation on catalytic hydrogenation. During World War I he was in charge of providing food to the destitute. Somogyi was invited to return to the United States by Philip A. Shaffer, whom he had known at Cornell. In 1922 Somogyi became an instructor in biochemistry at Washington University School of Medicine. There Somogyi worked with Shaffer and Edward Adelbert Doisy on insulin preparation and insulin's use in the treatment of diabetes. In 1926, Somogyi became the first biochemist on the staff of the new Jewish Hospital of St. Louis where he worked closely with physicians. He directed the hospital's clinical laboratory until he retired in 1957.
Sources: en.wikipedia.org
=== DNA testing === After a disease-causing mutation has been identified in an index case (which is not always accomplished conclusively), the main task is genetic identification of carriers within a pedigree, a sequential process known as "cascade testing". Family members with the same mutation may show different severities of disease, a phenomenon known as "variable penetrance". As a result, some may remain asymptomatic, with little lifelong evidence of disease. Nevertheless, their children remain at risk of inheriting the disorder and potentially being more severely affected.
At that time, the drug had not been discontinued and was considered a treatment for hereditary angioedema. In March 2009, Lundbeck purchased Ovation In 2010, Lundbeck withdrew stanozolol from the market in the US; as of 2014 no other company is marketing stanozolol as a pharmaceutical drug in the US but it can be obtained via a compounding pharmacy. Pfizer had marketed stanozolol as a veterinary drug; in 2013 Pfizer spun off its veterinary business to Zoetis and in 2014 Pfizer transferred the authorizations to market injectable and tablet forms of stanozolol as a veterinary drug to Zoetis. It is used in veterinary medicine as an adjunct in the management of wasting diseases, to stimulate the formation of red blood cells, arouse appetite, and promote weight gain, but the evidence for these uses is weak. It is used as a performance-enhancing drug in race horses. Its side effects include weight gain, water retention, and difficulty eliminating nitrogen-based waste products and it is toxic to the liver, especially in cats. Because it may promote the growth of tumors, it is contraindicated in dogs with enlarged prostates. Stanozolol and other AAS were commonly used to treat hereditary angioedema attacks, until several drugs were brought to market specifically for treatment of that disease, the first in 2009: Cinryze, Berinert, ecallantide (Kalbitor), icatibant (Firazyr) and Ruconest. Stanozolol is still used long-term to reduce the frequency of severity of attacks.
=== Signalling of fetal maturation and parturition === As pregnancy advances to term, the fetal membranes undergo weakening. The amnion is vital in the synthesis of prostaglandins which reach the myometrium and create and initiate parturition. The chorion expresses chemicals that balance synthesis and metabolism of these prostaglandins to ensure that the myometrium is not activated pre-term. Prostaglandin E2 is thought to be synthesized by cells in the amnion and is essential in dilation of the cervix at the initiation of parturition. Glucocorticoids have been implicated in fetal maturation, regulation of immune response and many other pregnancy associated changes. As well as its function in parturition, Prostaglandin E2 is vital for fetal lung maturation. Additionally, there is an abundance of 11β-hydroxysteroid dehydrogenase 1 expressed in the foetal membranes. This enzyme converts biologically inactive cortisone into active cortisol, another chemical vital for fetal maturation and labour initiation.
Sources: en.wikipedia.org
Creatine is the base compound, while creatine monohydrate includes one water molecule per creatine molecule in its crystal structure. The monohydrate form is common in supplements and analytical standards. The body uses creatine itself after the water is removed or dissociated.
Yes. Meat, fish, and other animal tissues contain creatine. Cooking can convert some creatine to creatinine, which has no role in phosphocreatine energy buffering. Plant foods contain little or no creatine.
Creatinine is a cyclic breakdown product formed from creatine and phosphocreatine. It is filtered by the kidneys and commonly measured in blood and urine as a marker of renal function. Creatine monohydrate is a supplement ingredient and research chemical, not the same molecule.
Purity is commonly assessed by HPLC, which separates creatine from related compounds such as creatinine. Water content is measured separately by Karl Fischer titration. Together these results help calculate the actual creatine content in a sample.